Discontinue use in patients w/ rhegmatogenous retinal detachment, or stage 3 or 4 macular holes. Endophthalmitis, intraocular inflammation, traumatic cataract, retinal detachment; retinal vasculitis &/or vascular occlusion; risk factors for retinal pigment epithelial tears. History of stroke, transient ischaemic attacks or MI w/in last 3 mth. Immunogenicity. Bilateral treatment. Monitor & manage for increased IOP & optic nerve head perfusion. Not to be used concurrently w/ other systemic or local anti-VEGF medicinal products. Hepatic impairment. May affect ability to drive or use machines. Women of childbearing potential should use effective contraception. Not to be used during pregnancy. Not recommended in lactation. Childn & adolescents <18 yr.